Partnership between AOP Orphan and Ferrer: Joint marketing of Adasuve® in CEE
AOP Orphan and Ferrer Internacional are expanding their long-standing partnership to include the marketing of the anti-psychotic drug Adasuve® (Staccato® Loxapine) in Central and Eastern Europe.
AOP Orphan and Ferrer Internacional are expanding their long-standing partnership to include the marketing of the anti-psychotic drug Adasuve® (Staccato® Loxapine) in Central and Eastern Europe. Adasuve® has been developed to provide rapid treatment for agitation in patients suffering from schizophrenia or manic depression. It combines the patented Staccato system with loxapine, a well-established anti-psychotic. The Staccato system – a hand-held, single-dose inhaler – allows the active agent to reach the lungs very quickly, meaning that it works just as swiftly as an intravenous injection. Consequently, Adasuve® is an easy-to-use and very reliable form of inhalation therapy, which quickly relieves the patient’s agitation.
The Austrian pharmaceutical company AOP Orphan markets Adasuve® in Austria, Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Switzerland, Slovakia and Slovenia. Other regions are currently being discussed. With this partnership, AOP Orphan has once again demonstrated its innovative spirit and ability to expand. “There is a very large clinical demand for this indication, which up to now has not been met, and we strongly believe that this untapped market will meet the forecast growth expectations,” says Dr. Rudolf Widmann, founder and CEO of AOP Orphan. “Adasuve® represents a breakthrough in the treatment of agitation and will fundamentally change the way in which psychiatrists treat such patients.”
About AOP Orphan
AOP Orphan researches, develops, produces and distributes innovative drugs and administration methods to treat rare diseases – and has become a European pioneer in the field of orphan diseases. The company’s focus is on the areas hematology and oncology, cardiology and pulmonology, neurology and psychiatry, and metabolic diseases. AOP Orphan is one of the foremost providers in the sector, generating a turnover of more than EUR 50 million as an Austrian company with transnational operations. It has an export ratio of around 70% and employs over 100 people. The rare disease specialist has branch offices situated in its core markets within the EU, Switzerland and the Middle East. The international markets are handled and operated by long-term, close partners of the company, AOP Orphan has a total of twelve locations.